

NCoA-3 (C-20): sc-7216

BACKGROUND

Nuclear receptors for steroids, thyroid hormones and retinoic acids are ligand-dependent transcription factors that activate transcription through specific DNA binding sites in their target genes. Several related transcriptional co-activators and co-repressors have been described that work in concert with the steroid receptor family to either induce or repress transcription from hormone-responsive elements. This family includes GRIP1 (for GR interacting protein 1), also designated NCoA-2 or TIF2; SRC-1 (for steroid receptor co-activator-1), also designated NCoA-1; NCoA-3, also designated RAC-3, ACTR, AIB-1 (for amplified in breast cancer); and p/CIP (for p300/CBP/co-integrator protein), which displays elevated expression in estrogen receptor positive ovarian and breast cancers and is required for the transcriptional activation of p300/CBP-dependent transcription factors.

CHROMOSOMAL LOCATION

Genetic locus: NCOA3 (human) mapping to 20q13.12; Ncoa3 (mouse) mapping to 2 H3.

SOURCE

NCoA-3 (C-20) is an affinity purified goat polyclonal antibody raised against a peptide mapping at the C-terminus of NCoA-3 of human origin.

PRODUCT

Each vial contains 200 µg IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Also available as TransCruz reagent for ChIP application, sc-7216 X, 200 µg/0.1 ml.

Blocking peptide available for competition studies, sc-7216 P, (100 µg peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

APPLICATIONS

NCoA-3 (C-20) is recommended for detection of NCoA-3 of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500), immunohistochemistry (including paraffin-embedded sections) (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

NCoA-3 (C-20) is also recommended for detection of NCoA-3 in additional species, including equine, canine, bovine and porcine.

Suitable for use as control antibody for NCoA-3 siRNA (h): sc-29636, NCoA-3 siRNA (m): sc-29637, NCoA-3 shRNA Plasmid (h): sc-29636-SH, NCoA-3 shRNA Plasmid (m): sc-29637-SH, NCoA-3 shRNA (h) Lentiviral Particles: sc-29636-V and NCoA-3 shRNA (m) Lentiviral Particles: sc-29637-V.

NCoA-3 (C-20) X TransCruz antibody is recommended for ChIP assays.

Molecular Weight of NCoA-3: 160 kDa.


RESEARCH USE

For research use only, not for use in diagnostic procedures.


STORAGE

Store at 4° C, ****DO NOT FREEZE****. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

DATA



NCoA-3 (C-20): sc-7216. Western blot analysis of NCoA-3 expression in rat testis tissue extract.



NCoA-3 (C-20): sc-7216. Immunoperoxidase staining of formalin-fixed, paraffin-embedded human pancreas tissue showing cytoplasmic staining.

SELECT PRODUCT CITATIONS

- Chen, S.L., et al. 2001. Subcellular localization of the steroid receptor co-activators (SRCs) and MEF2 in muscle and rhabdomyosarcoma cells. *Mol. Endocrinol.* 15: 783-796.
- Katiyar, P., et al. 2009. Mechanism of BRCA1-mediated inhibition of progesterone receptor transcriptional activity. *Mol. Endocrinol.* 23: 1135-1146.
- Ellison-Zelski, S.J., et al. 2009. Repression of ESR1 through actions of estrogen receptor α and Sin3A at the proximal promoter. *Mol. Cell. Biol.* 29: 4949-4958.
- Turunen, M.P., et al. 2009. Efficient regulation of VEGF expression by promoter-targeted lentiviral shRNAs based on epigenetic mechanism: a novel example of epigenetherapy. *Circ. Res.* 105: 604-609.
- Asano, J., et al. 2010. Histone acetylation and steroid receptor coactivator expression during clofibrate-induced rat hepatocarcinogenesis. *Cancer Sci.* 101: 869-875.
- Lanz, R.B., et al. 2010. Global characterization of transcriptional impact of the SRC-3 coregulator. *Mol. Endocrinol.* 24: 859-872.
- Song, Y., et al. 2011. Ligand-dependent corepressor acts as a novel corepressor of thyroid hormone receptor and represses hepatic lipogenesis in mice. *J. Hepatol.* 56: 248-254.
- Jeyakumar, M., et al. 2011. Exploration of dimensions of estrogen potency: parsing ligand binding and coactivator binding affinities. *J. Biol. Chem.* 286: 12971-12982.

MONOS
Satisfaction
Guaranteed

Try **NCoA-3 (F-2): sc-5305** or **NCoA-3 (B-3): sc-515530**, our highly recommended monoclonal alternatives to NCoA-3 (C-20).